CN110352057A - 治疗癌症的卡博替尼与阿特珠单抗组合 - Google Patents

治疗癌症的卡博替尼与阿特珠单抗组合 Download PDF

Info

Publication number
CN110352057A
CN110352057A CN201880013200.7A CN201880013200A CN110352057A CN 110352057 A CN110352057 A CN 110352057A CN 201880013200 A CN201880013200 A CN 201880013200A CN 110352057 A CN110352057 A CN 110352057A
Authority
CN
China
Prior art keywords
subjects
cabozantinib
dose
compound
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880013200.7A
Other languages
English (en)
Chinese (zh)
Inventor
G·施瓦布
C·谢佛德
C·海塞尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Priority to CN202311144084.1A priority Critical patent/CN117771363A/zh
Priority to CN202311144073.3A priority patent/CN117205312A/zh
Priority to CN202311144074.8A priority patent/CN117205313A/zh
Publication of CN110352057A publication Critical patent/CN110352057A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201880013200.7A 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合 Pending CN110352057A (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202311144084.1A CN117771363A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合
CN202311144073.3A CN117205312A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合
CN202311144074.8A CN117205313A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762448869P 2017-01-20 2017-01-20
US62/448,869 2017-01-20
US201762458447P 2017-02-13 2017-02-13
US62/458,447 2017-02-13
PCT/US2018/014523 WO2018136796A1 (en) 2017-01-20 2018-01-19 Combinations of cabozantinib and atezolizumab to treat cancer

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202311144074.8A Division CN117205313A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合
CN202311144084.1A Division CN117771363A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合
CN202311144073.3A Division CN117205312A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合

Publications (1)

Publication Number Publication Date
CN110352057A true CN110352057A (zh) 2019-10-18

Family

ID=61569414

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201880013200.7A Pending CN110352057A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合
CN202311144073.3A Pending CN117205312A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合
CN202311144084.1A Pending CN117771363A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合
CN202311144074.8A Pending CN117205313A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202311144073.3A Pending CN117205312A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合
CN202311144084.1A Pending CN117771363A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合
CN202311144074.8A Pending CN117205313A (zh) 2017-01-20 2018-01-19 治疗癌症的卡博替尼与阿特珠单抗组合

Country Status (15)

Country Link
US (2) US11198731B2 (enExample)
EP (1) EP3570840B1 (enExample)
JP (3) JP7222895B2 (enExample)
KR (2) KR102610764B1 (enExample)
CN (4) CN110352057A (enExample)
AU (2) AU2018210397B2 (enExample)
BR (1) BR112019015011A2 (enExample)
CA (1) CA3049452A1 (enExample)
ES (1) ES3031468T3 (enExample)
IL (1) IL268138B (enExample)
MA (1) MA47310A (enExample)
MX (2) MX389966B (enExample)
UA (1) UA126970C2 (enExample)
WO (1) WO2018136796A1 (enExample)
ZA (1) ZA201904652B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2628418T3 (es) 2010-05-20 2017-08-02 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la TRK cinasa
EP3174854B1 (en) 2014-07-31 2022-08-24 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
CA3020749A1 (en) 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2018136796A1 (en) * 2017-01-20 2018-07-26 Exelixis, Inc. Combinations of cabozantinib and atezolizumab to treat cancer
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
SG11202006921PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
JP7653352B2 (ja) * 2018-09-05 2025-03-28 エクスプレステック、リミテッド、ライアビリティ、カンパニー 免疫グロブリンａ製剤
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての縮合複素環式化合物
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
US20230301979A1 (en) * 2020-07-31 2023-09-28 Exelixis, Inc. Combinations for the treatment of cancer
US20230314440A1 (en) * 2020-08-21 2023-10-05 Exelixis, Inc. Method of treating cancer
EP4308243A4 (en) * 2021-03-19 2025-02-26 Merck Sharp & Dohme LLC METHODS FOR TREATING CANCER WITH ANTI-ILT3 ANTIBODIES
US11620580B2 (en) * 2021-04-01 2023-04-04 Banjo Health Inc. Methods and systems for probabilistic filtering of candidate intervention representations
CN120417903A (zh) 2023-01-31 2025-08-01 汉达癌症医药责任有限公司 改良的卡博替尼组合物及其使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
US20080200515A1 (en) 2006-12-29 2008-08-21 Tap Pharmaceutical Products Inc. Solid state forms of enantiopure ilaprazole
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
DK2387563T4 (da) * 2009-01-16 2022-07-18 Exelixis Inc Malatsalt af n-(4-{ [ 6, 7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid, og krystallinske former deraf til behandling af cancer
EP2593090B1 (en) 2010-07-16 2021-10-13 Exelixis, Inc. C-met modulator pharmaceutical compositions
BR112015025408A8 (pt) * 2013-04-04 2018-07-10 Exelixis Inc combinações de drogas para tratar câncer
MX384828B (es) * 2014-02-14 2025-03-14 Exelixis Inc Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.
CA3020749A1 (en) 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
EP3445361A1 (en) * 2016-04-19 2019-02-27 Exelixis, Inc. Triple negative breast cancer treatment method
WO2018136796A1 (en) * 2017-01-20 2018-07-26 Exelixis, Inc. Combinations of cabozantinib and atezolizumab to treat cancer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A.B. APOLO等: "A phase I study of cabozantinib plus nivolumab (CaboNivo) in patients (pts) refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors", 《ANNALS OF ONCOLOGY》 *
BERNARD ESCUDIER等: "Cabozantinib for the treatment of renal cell carcinoma", 《EXPERT OPINION ON PHARMACOTHERAPY》 *
EXELIXIS: "History of Changes for Study: NCT03170960,Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally", 《CLINICAL TRIALS.GOV》 *
GABRIEL G. MALOUF等: "Therapeutic Strategies for Patients With Metastatic Renal Cell Carcinoma in Whom First-Line Vascular Endothelial Growth Factor Receptor–Directed Therapies Fail", 《JOURNAL OF ONCOLOGY PRACTICE》 *
POWLES T. 等: "Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma and Urothelial Carcinoma", 《EUR UROL SUPPL》 *
STEVEN S YU等: "Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection", 《ONCOTARGETS AND THERAPY》 *
THOMAS E. HUTSON等: "The Evolution of Systemic Therapy in Metastatic Renal Cell Carcinoma", 《ASCO EDUCATIONAL BOOK》 *

Also Published As

Publication number Publication date
MX389966B (es) 2025-03-20
CN117771363A (zh) 2024-03-29
WO2018136796A1 (en) 2018-07-26
CN117205313A (zh) 2023-12-12
MX2022001718A (es) 2022-03-11
KR20190107103A (ko) 2019-09-18
ES3031468T3 (en) 2025-07-09
US20190352403A1 (en) 2019-11-21
JP7222895B2 (ja) 2023-02-15
US20220056138A1 (en) 2022-02-24
BR112019015011A2 (pt) 2020-04-28
MA47310A (fr) 2019-11-27
KR102610764B1 (ko) 2023-12-07
JP2024019720A (ja) 2024-02-09
IL268138A (en) 2019-09-26
AU2024203472A1 (en) 2024-06-13
MX2019008032A (es) 2019-12-16
ZA201904652B (en) 2024-11-27
CA3049452A1 (en) 2018-07-26
UA126970C2 (uk) 2023-03-01
KR20230169458A (ko) 2023-12-15
AU2018210397A1 (en) 2019-07-25
US11198731B2 (en) 2021-12-14
NZ755494A (en) 2025-06-27
JP2022121594A (ja) 2022-08-19
AU2018210397B2 (en) 2024-02-29
CN117205312A (zh) 2023-12-12
IL268138B (en) 2022-08-01
EP3570840B1 (en) 2025-03-19
EP3570840A1 (en) 2019-11-27
JP2020514311A (ja) 2020-05-21

Similar Documents

Publication Publication Date Title
US11198731B2 (en) Combinations of cabozantinib and atezolizumab to treat cancer
US20160082019A1 (en) Drug Combinations to Treat Cancer
JP7579781B2 (ja) Ｃｄｃ７阻害剤を含む癌の治療方法
KR20250056270A (ko) 활성화 fgfr3 유전자 변화를 갖는 고형 종양을 치료하는 방법
WO2022089377A1 (en) Combination of a pd-1 or pd-l1 antagonist and a vegfr inhibitor for treating cancer
JP2020536068A (ja) 癌を治療するための組成物および治療方法
HK40016051A (en) Combinations of cabozantinib and atezolizumab to treat cancer
HK40018507B (en) Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer
HK40018507A (en) Combinations of cabozantinib and atezolizumab for the treatment of castration-resistant prostate cancer
NZ795674A (en) Combinations of cabozantinib and atezolizumab to treat cancer
EA041548B1 (ru) Способ лечения локальных поздних стадий солидных опухолей или метастатических солидных опухолей
WO2020039401A1 (en) Treatment comprising il-1βeta binding antibodies and combinations thereof
Zeng et al. Adebrelimab combined with anlotinib plus hepatic arterial infusion chemotherapy or intravenous chemotherapy for first-line treatment of advanced biliary tract cancer: protocol for a randomized open-label clinical study
Dai et al. Capecitabine and Oxaliplatin (CAPEOX) combined with Sintilimab plus bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or esophagogastric junction adenocarcinoma: study protocol of a single-arm, phase Ib/II trial
WO2025104045A1 (en) Alectinib for the treatment of alk fusion-positive solid or cns tumours
KR20240162547A (ko) 화학요법과 조합하여 항-pd-l1 항체를 사용하여 담도암을 치료하는 방법
Wei A Phase II, Single-center, Single-arm Clinical Trial on the Efficacy and Safety of Anti-PD-1 antibody (IBI308) Combined with Anlotinib for the Treatment of Recurrent or Advanced Endometrial Cancer
Carthon Winship Protocol#: Winship4643-19 TITLE: A Phase 2 Study of Neoadjuvant Cabozantinib in Patients with Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40016051

Country of ref document: HK